Abstract
Cardiovascular disease is the principal complication and the leading cause of death for patients with diabetes (DM). The efficacy of antihyperglycemic treatments on cardiovascular disease risk remains uncertain. Cardiovascular risk factors are affected by antihyperglycemic medications, as are many intermediate markers of cardiovascular disease. Here we summarize the evidence assessing the cardiovascular effects of antihyperglycemic medications with regard to risk factors, intermediate markers of disease, and clinical outcomes.
© 2015 American Society for Clinical Pharmacology and Therapeutics.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Biomarkers / blood
-
Blood Glucose / drug effects*
-
Blood Glucose / metabolism
-
Cardiovascular Diseases / chemically induced
-
Cardiovascular Diseases / diagnosis
-
Cardiovascular Diseases / epidemiology*
-
Comorbidity
-
Diabetes Complications / diagnosis
-
Diabetes Complications / epidemiology*
-
Diabetes Mellitus / blood
-
Diabetes Mellitus / diagnosis
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus / epidemiology
-
Humans
-
Hypoglycemic Agents / adverse effects*
-
Risk Assessment
-
Risk Factors
-
Treatment Outcome
Substances
-
Biomarkers
-
Blood Glucose
-
Hypoglycemic Agents